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Foreword
As the largest organ of the body, the skin performs multiple critical functions, such as 
serving as the primary barrier to the external environment. For this reason, the skin is 
often exposed to potentially hazardous agents, including chemicals, which may contribute 
to the onset of a spectrum of adverse health effects ranging from localized damage (e.g., 
irritant contact dermatitis and corrosion) to induction of immune-mediated responses 
(e.g., allergic contact dermatitis and pulmonary responses), or systemic toxicity (e.g., 
neurotoxicity and hepatoxicity). Understanding the hazards related to skin contact with 
chemicals is a critical component of modern occupational safety and health programs.
In 2009, the National Institute for Occupational Safety and Health (NIOSH) pub-
lished Current Intelligence Bulletin (CIB) 61: A Strategy for Assigning New NIOSH Skin 
Notations [NIOSH 2009–147]. This document provides the scientific rationale and 
framework for the assignment of multiple hazard-specific skin notations (SK) that 
clearly distinguish between the systemic effects, direct (localized) effects, and immune- 
mediated responses caused by skin contact with chemicals. The key step within assign-
ment of the hazard-specific SK is the determination of a substance’s hazard potential, or 
its potential for causing adverse health effects as a result of skin exposure. This determi-
nation entails a health hazard identification process that involves use of the following:
 • Scientific data on the physicochemical properties of a chemical
 • Data on human exposures and health effects
 • Empirical data from in vivo and in vitro laboratory testing
 • Computational techniques, including predictive algorithms and mathematical 
models that describe a selected process (e.g., skin permeation) by means of ana-
lytical or numerical methods. 
This Skin Notation Profile provides the SK assignment and supportive data for 
2- butoxyethanol (BE; CAS No. 111–76–2). In particular, this document evaluates and 
summarizes the literature describing the substance’s hazard potential and its assess-
ment according to the scientific rationale and framework outlined in CIB 61. In meet-
ing this objective, this Skin Notation Profile intends to inform the audience—mostly 
occupational health practitioners, researchers, policy- and decision-makers, employers, 
and workers in potentially hazardous workplaces—so that improved risk-management 
practices may be developed to better protect workers from the risks of skin contact with 
the chemical of interest. 
John Howard, M.D. 
Director, National Institute for  
   Occupational Safety and Health 
Centers for Disease Control and Prevention
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Abbreviations
ACGIH American Conference of Governmental Industrial Hygienists 
ATSDR Agency for Toxic Substances and Disease Registry
BE 2-Ethoxyethanol
CIB Current Intelligence Bulletin
cm2 square centimeter(s)
cm/hr centimeter(s) per hour
cm/s centimeter(s) per second
DEREK™ Deductive Estimation of Risk from Existing Knowledge
DIR skin notation indicating the potential for direct effects to the skin 
   following contact with a chemical
EC European Commission 
EEC European Economic Communities
g gram(s)
GHS Globally Harmonized System of Classification and Labeling of Chemicals
GPMT guinea pig maximization test
IARC International Agency for Research on Cancer
IPCS International Program for Chemical Safety 
(IRR) subnotation of SK: DIR indicating the potential for a chemical to be a 
   skin irritant following exposure to the skin
Kaq  coefficient in the watery epidermal layer 
Kp skin permeation coefficient 
Kpol  coefficient in the protein fraction of the stratum corneum
Kpsc permeation coefficient in the lipid fraction of the stratum corneum 
LD50  dose resulting in 50% mortality in the exposed population
LDLo dermal lethal dose
LOAEL lowest-observed-adverse-effect level 
log KOW base-10 logarithm of a substance’s octanol–water partition
m3 cubic meter(s)
mg milligram(s)
mg/cm2/hr milligram(s) per square centimeter per hour
mg/cm2/min  milligram(s) per square centimeter per minute
mg/kg milligram(s) per kilogram body weight
mg/kg/day milligram(s) per kilogram body weight per day
mg/mL milligram(s) per milliliter
mg/m3 milligram(s) per cubic meter
mL milliliter(s)
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mL/kg milliliter(s) per kilogram body weight
MW molecular weight
NIOSH National Institute for Occupational Safety and Health
NOAEL no-observed-adverse-effect level
NTP National Toxicology Program
OEL occupational exposure limit
OSHA Occupational Safety and Health Administration
REL recommended exposure limit
RF retention factor 
SEN skin notation indicating the potential for immune-mediated reactions 
   following exposure of the skin
SI ratio ratio of skin dose to inhalation dose
SK skin notation
SW  solubility 
SYS skin notation indicating the potential for systemic toxicity following 
exposure of the skin
USEPA United States Environmental Protection Agency 
μg/cm2  microgram(s) per square centimeter
μL microliter(s)
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Glossary 
Absorption—The transport of a chemical from the outer surface of the skin into both 
the skin and systemic circulation (including penetration, permeation, and resorption). 
Acute exposure—Contact with a chemical that occurs once or for only a short period 
of time. 
Cancer—Any one of a group of diseases that occurs when cells in the body become 
abnormal and grow or multiply out of control. 
Contaminant—A chemical that is (1) unintentionally present within a neat substance 
or mixture at a concentration less than 1.0% or (2) recognized as a potential carcinogen 
and present within a neat substance or mixture at a concentration less than 0.1%. 
Cutaneous (or percutaneous)—Referring to the skin (or through the skin). 
Dermal—Referring to the skin. 
Dermal contact—Contact with (touching) the skin. 
Direct effects—Localized, non-immune-mediated adverse health effects on the skin, 
including corrosion, primary irritation, changes in skin pigmentation, and reduction/
disruption of the skin barrier integrity, occurring at or near the point of contact with 
chemicals. 
Immune-mediated responses—Responses mediated by the immune system, including 
allergic responses. 
Sensitization—A specific immune-mediated response that develops following expo-
sure to a chemical, which, upon re-exposure, can lead to allergic contact dermatitis 
(ACD) or other immune-mediated diseases such as asthma, depending on the site and 
route of re-exposure. 
Substance—A chemical. 
Systemic effects—Systemic toxicity associated with skin absorption of chemicals after 
exposure of the skin.
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1.2 Purpose
This Skin Notation Profile presents (1) a 
brief summary of technical data associat-
ed with skin contact with BE and (2) the 
rationale behind the hazard-specific skin 
notation (SK) assignment for BE. The SK 
assignment is based on the scientific ra-
tionale and logic outlined in the Current 
Intelligence Bulletin (CIB) 61: A Strategy 
for Assigning New NIOSH Skin Notations 
[NIOSH 2009]. The summarized infor-
mation and health hazard assessment are 
limited to an evaluation of the potential 
health effects of dermal exposure to BE. 
A literature search was conducted through 
July 2010 to identify information on BE, 
including but not limited to data relating 
to its toxicokinetics, acute toxicity, repeat-
ed-dose systemic toxicity, carcinogenicity, 
biological system/function–specific effects 
(including reproductive and developmen-
tal effects and immunotoxicity), irritation, 
and sensitization. Information was con-
sidered from studies of humans, animals, 
or appropriate modeling systems that are 
relevant to assessing the effects of dermal 
exposure to BE. 
1.3 Overview of SK Assignment for BE
BE is potentially capable of causing mul-
tiple toxic effects following skin contact. A 
critical review of available data has resulted 
in the following SK assignment for BE: 
SK: SYS-DIR (IRR). Table 1 provides 
an overview of the critical effects and data 
used to develop the SK assignment for BE. 
2 Systemic Toxicity from Skin 
Exposure (SK: SYS)
Several toxicokinetic studies following 
dermal exposure to BE were identified, 
and significant percutaneous absorption 
has been demonstrated in humans and 
animals in vivo and through human and 
animal skin in vitro. Jakasa et al. [2004] re-
ported greater percutaneous absorption of 
BE as an aqueous solution than as a neat 
substance, after six male volunteers were 
dermally exposed for 4 hours on the volar 
forearm, over an area of 40 square cen-
timeters (cm2). After exposure to a 50% 
solution (BE dissolved in water), a 90% 
solution, or neat BE, the time-weighted 
1 Introduction
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2-Butoxyethanol (BE) is an organic 
compound used primarily as a sol-
vent and chemical intermediate 
[ATSDR 1998].
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average dermal fluxes from a 24-hours 
cumulative period were 1.34, 0.92, and 
0.26 milligram per square centimeter per 
hour (mg/cm2/hr), respectively. Kezic et 
al. [2004] also reported an average der-
mal flux of 3.5 mg/cm2/hr, based on free 
or total butoxyethanoic acid appearing in 
the urine of volunteers following dermal 
exposure to 50% of the substance in wa-
ter, under the same conditions as in the 
study of Jakasa et al. (2004). In vivo per-
meability coefficients (Kp) of 1.75 × 10-3 
and 0.88 × 10-3 centimeter per hour (cm/
hr) for 50% and 90% aqueous solutions of 
BE, respectively, have been reported for 
humans [ Jakasa et al. 2004], and Kp of 0.3 
× 10-3, 0.84 × 10-3, and 1.82 × 10-3 cm/hr 
for neat, 80%, and 40% aqueous solutions 
of BE have been reported for guinea pigs 
[ Johanson and Fernstrom 1988]. The hu-
man Kp values for BE were estimated to 
be 2 cm/hr and 4 cm/hr, respectively, for 
normal temperature and relative humid-
ity (23oC and 29%) and elevated tem-
perature and humidity (33oC and 71%) 
[Corley et al. 1997]. Following in vitro 
studies of human skin exposed to either 
an aqueous solution of BE [3 milligrams 
per milliliter (mg/mL)] or undiluted BE, 
Wilkinson and Williams [2002] reported 
higher apparent Kp values with the aque-
ous solution [dose, 200 microliters (μL); 
L; Kp, 64.3 mg/cm2/hr] than with undi-
luted BE [dose, 10.5 μL; Kp, 30.8 mg/cm2/
hr]. Johanson et al. [1988] reported percu-
taneous uptake of neat liquid BE at a rate 
of 0.83–11.33 milligram per square centi-
meter per minute (mg/cm2/min), based on 
measured blood levels in 12 experiments 
involving five volunteers, who had two or 
four fingers exposed to the neat substance 
for 2 hours. Sufficient data are available 
from toxicokinetic studies in both humans 
and animals [Bartnik et al. 1987; Sabourin 
et al. 1992, 1993; Jakasa et al. 2004] to 
demonstrate that BE is absorbed through 
the skin following dermal exposure.
In in vivo percutaneous absorption stud-
ies in rats, Bartnik et al. [1987] estimated 
dermal absorption of 25% to 29% of the 
applied topical dose, calculated on the 
basis of urinary excretion of radioactiv-
ity following topical and subcutaneous 
administration of BE. In that study, 200 
milligrams per kilograms body weight 
(mg/kg) of BE in water was applied to a 
12-cm2 area of shaved rat skin under oc-
clusive conditions. Sabourin et al. [1992, 
1993] reported dermal absorption values 
of 21% to 25% of the applied dose, based 
on measurements of excretion of 14C, fol-
lowing 72-hours dermal application of 
BE in acetone ranging in concentration 
from 53.2 to 472.7 mg/kg to shaved rat 
skin under semiocclusive conditions. 
In in vitro percutaneous studies of dorsal 
skin of hairless rats, dorsal domestic pig 
skin, and human skin from the flexus side 
of the arm, Bartnik et al. [1987] found 
that dermal absorption increases with 
time of exposure and that absorption is 
greater under semiocclusive conditions 
than under nonocclusive conditions. Us-
ing undiluted (100%) BE, Bartnik et al. 
[1987] reported time-course absorption 
(percent of applied radioactivity) of 19.4% 
(after 1 hour), 66.7% (after 6 hours), and 
Table 1. Summary of the SK assignment for BE
Skin notation Critical effect Data available
SK: SYS Hemoglobinuria (and 
other blood effects)
Limited human data; sufficient animal data
SK: DIR (IRR) Skin irritation Limited human data; sufficient animal data
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94.3% (after 16 hours) in rat skin under 
semiocclusive conditions. The authors re-
ported that only 5.6% of the applied does 
was absorbed after 1 hour in hairless rat 
skin under nonocclusive conditions, while 
11.2% of the applied dose was absorbed 
after 6 hours in pig skin under semioc-
clusive conditions. The results of the study 
indicate that dermal uptake of BE varies 
based on exposure scenario (nonoccluded 
vs. occluded) and type of skin (rat vs. pig) 
used within the experiment. 
When the substance was diluted in wa-
ter, a 10% concentration applied to 100 
micrograms per square centimeter (μg/
cm2) of the skin under semiocclusive con-
ditions for 1 hour resulted in dermal ab-
sorption of 17.3% (human), 17.7% (pig), 
and 43.3% (rat). Under nonocclusive con-
ditions, the same concentration applied to 
the same area of skin yielded absorption 
of 6.9% (human), 8.6% (pig), and 11.0% 
(rat). For absorption of BE through hu-
man abdominal epidermis in an in vitro 
system [Dugard et al. 1984], a rate of 0.2 
mg/cm2/hr was reported. 
Corley et al. [1997], using physiologically 
based pharmacokinetic modeling, report-
ed dermal absorption of 15% to 27% of 
the total uptake of BE vapors (50 parts 
per million [ppm] for 2 hours) for worst-
case exposure scenarios (no clothing and 
exposure of 100% of the total body sur-
face) and 4.4% to 8.4% for more realistic 
exposures (25% of the surface area, such as 
parts of both arms and head). The poten-
tial of BE to pose a skin absorption hazard 
was also evaluated with a predictive algo-
rithm for estimating and evaluating the 
health hazards of dermal exposure to sub-
stances [NIOSH 2009]. The evaluation 
method compares an estimated chemical 
dose accumulated in the body from skin 
absorption and an estimated dose from 
respiratory absorption associated with a 
reference occupational exposure limit. On 
the basis of this algorithm, a ratio of the 
skin dose to the inhalation dose (SI ratio) 
of 27.7 was calculated for BE. An SI ratio 
of ≥0.1 indicates that a chemical is capable 
of producing systemic toxicity from skin 
exposure [NIOSH 2009]. Additional in-
formation on the SI ratio and the variables 
used in its calculation are included in the 
appendix. 
Although no dermal lethal concentration 
(LDLo) for humans has been identified, the 
reported values for dermal LD50 (the dose 
resulting in 50% mortality in the exposed 
population) of undiluted BE ranged from 
0.11 to 0.56 milligrams per kilogram body 
weight (mL/kg), which corresponded to 
99 to 505 mg/kg [Carpenter et al. 1956; 
Duprat and Gradiski 1979] under occlu-
sive conditions and 2.0 mL/kg (1,804 mg/
kg) under nonocclusive conditions [Car-
penter et al. 1956] for rabbits. A value of 
1.59 mL/kg to 2.52 mL/kg (correspond-
ing to 1434 to 2271 mg/kg) was report-
ed for rats (Union Carbide Corporation 
1972). Because the reported acute der-
mal LD50 values for rabbits are generally 
lower than the critical dermal LD50 value 
of 2000 mg/kg body weight that identifies 
chemical substances with the potential for 
acute dermal toxicity [NIOSH 2009], BE 
is considered acutely toxic following der-
mal exposure. 
No chronic toxicity studies of dermal ex-
posure in humans or animals were iden-
tified. However, a 13-week, subchronic 
dermal toxicity study was conducted in 
rabbits under the sponsorship of the Wil 
Research Laboratories [1983]. The ani-
mals were treated with BE at dose levels 
of 10, 50, or 150 milligrams per kilogram 
body weight per day (mg/kg/day) through 
the topical application of approximately 1 
milliliter (mL) of 2.8%, 14.3%, or 42.8% 
aqueous solution, respectively, for 6 hours 
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a day for 5 days/week. In that study, the 
highest dose of 150 mg/kg/day elicited 
no systemic effects and, hence, was re-
garded as the no-observed-adverse-effect 
level (NOAEL). In a shorter study (Union 
Carbide Corporation 1980b) that formed 
the basis for the subchronic study, rabbits 
were administered 1 mL of a 100%, 50%, 
25%, or 5% solution of BE (reported by 
Tyler [1984] as 360, 180, 90, and 18 mg/
kg/day) under an occlusive condition for 6 
hours a day, 5 days/week, for nine applica-
tions over 11 days; this was followed by a 
14-day observation period. The undiluted 
BE (at 360 mg/kg/day) caused significant 
decreases in the rate of body weight gain, 
decreases in erythrocyte count and hemo-
globin concentration, and an increase in 
the mean corpuscular hemoglobin value 
for the females; it caused hemoglobinuria 
in both males and females. Hemoglobin-
uria was also noted in females exposed to 
the 50% aqueous dilution (180 mg/kg/
day), indicating that this was the lowest-
observed-adverse-effect level (LOAEL) 
in the short-term study. From these stud-
ies, a NOAEL of 150 mg/kg/day can be 
derived, with a LOAEL of 180 mg/kg/
day to protect against hemoglobinuria and 
other blood effects at higher doses. 
No epidemiological or case reports that 
evaluated reproductive or developmental 
toxicity following dermal exposure to BE 
were identified. No standard toxicity or 
specialty studies of biological system/func-
tion specific effects (including reproduc-
tive effects and immunotoxicity) following 
dermal exposure to BE were identified in 
animals. However, a study by Hardin et al. 
[1984] indicated that BE did not induce 
embryotoxic, fetotoxic, or teratogenic ef-
fects in rats dermally exposed four times/
day to 0.12 mL/application (0.48 mL/
day) of undiluted BE at 2.5-hr intervals on 
gestation days 7 to 16, followed by a 5-day 
postexposure period prior to death. The 
dose is calculated as 1880 mg/kg/day, based 
on the average body weight of 230 grams 
(g) computed from body weights reported 
by the authors on 4 days between gesta-
tion days 5 and 17 inclusive. There were 
no effects on body weight or body weight 
gain, gravid uterus weight, extragestational 
weight, or extragestational weight gain in 
treated animals, in comparison with con-
trols. The same investigators reported that 
dermal exposure to 0.35 mL/application 
four times a day (corresponding to 5490 
mg/kg/day) resulted in burgundy-colored 
urine by the end of the first treatment day, 
whereas continued treatment elicited atax-
ia, progressing to moderate to marked in-
activity; rough hair coats with dark stains 
around the muzzle and anogenital area; and 
then death in 10 of 11 rats. Based on the 
results of Hardin et al. [1984], the NOAEL 
for developmental effects was approximately 
1880 mg/kg/day.
No epidemiological or case reports that 
evaluated the potential of BE to cause 
cancer following dermal exposure to BE 
were identified. However, Jacobs et al. 
[1984] reported a dermal carcinogenicity 
study in mice in which a hair dye formula-
tion containing 10% BE was applied to the 
clipped skin (0.5 mL/application) three 
times weekly for 20 months. There were 
no statistically significant differences in 
the incidence of pulmonary adenomas or 
hepatic hemangiomas between treated and 
control groups. There are insufficient data 
to evaluate the carcinogenicity of BE fol-
lowing dermal exposure. Table 2 provides 
a summary of carcinogenic designations 
from multiple governmental and nongov-
ernmental organizations for BE. Taken 
together, findings of toxicokinetic studies 
in human and animals in vivo and in vitro 
[Bartnik et al. 1987; Sabourin et al. 1992, 
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1993; Jakasa et al. 2004*] and findings of 
systemic toxicity studies [Carpenter et al. 
1956; Union Carbide Corporation 1972; 
Duprat and Gradiski 1979; Union Car-
bide Corporation 1980b], supported by 
the results of mathematical modeling, are 
sufficient to conclude that BE is absorbed 
through the skin, is systemically available, 
and has the potential to cause hemoglo-
binuria (and other blood effects and body 
weight changes). Therefore, on the basis 
of the data for this assessment, BE is as-
signed the SK: SYS notation.
3 Direct Effects on Skin (SK: DIR)
The literature search yielded no data on 
the corrosivity of BE or data from in vi-
tro tests for corrosivity in human or ani-
mal skin models or for skin integrity in 
cadaver skin. However, skin irritation was 
observed in a repeated-insult patch test 
conducted in over 200 volunteers with a 
10% aqueous (volume/volume) solution 
of BE. This concentration was selected by 
the investigators [Greenspan et al. 1995] 
*References in bold text indicate studies that served 
as the basis of the SK assignment.
to simulate the highest concentration used 
in cosmetic products and because higher 
concentrations may be irritating. In that 
study, the substance caused few signs of 
irritation, only within the first 24 hours, 
but 25% of the volunteers had slight or 
definite erythema after multiple appli-
cations. During the challenge phase, the 
investigators observed slight erythema in 
only 7 and 12 of 200 subjects during the 
48-hours and 72-hours evaluations, re-
spectively, and only 1 of the 200 had defi-
nite irritation at the 72-hours evaluation.
A number of studies have evaluated the 
skin irritation potential of BE in experi-
mental animals. In a primary skin irrita-
tion test, Union Carbide Corporation 
(1972) concluded that the chemical is a 
slight skin irritant in rabbits. In a recent 
study, Zissu [1995] compared the skin ir-
ritation potential of the substance by us-
ing the Draize protocol and the European 
Economic Communities (EEC) method. 
With the Draize protocol, the undiluted 
substance was severely irritating to rabbit 
skin, whereas with the EEC method, it 
was irritating. However, earlier studies in 
rabbits yielded mixed results. In an acute 
study in which rabbits were administered 
Table 2. Summary of the carcinogenic designations* for BE by  numerous 
 governmental and nongovernmental organizations
Organization Carcinogenic designation 
NIOSH [2005] None
NTP [2009] None
USEPA [2009] Group C: Possible human carcinogen
IARC [2006] Group 3: Not classifiable as to carcinogenicity to humans
EC [2010] None
ACGIH [2003] None
Abbreviations: ACGIH = American Conference of Governmental Industrial Hygienists; EC = European Commission, Joint Re-
search, Institute for Health and Consumer Protection; IARC = International Agency for Research on Cancer; NIOSH = National 
Institute for Occupational Safety and Health; NTP = National Toxicology Program; USEPA = United States Environmental 
Protection Agency.
*Note: The listed cancer designations were based on data from nondermal (such as oral or inhalation) exposure rather than der-
mal exposure.
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0.08 to 0.25 mL/kg to the skin, Duprat 
and Gradiski [1979] reported that irrita-
tion and necrosis were time-dependent 
but not dose-dependent. However, Jacobs 
et al. [1984] reported that 0.5 mL of the 
test material (5%–50% in sweet almond 
oil), applied to the skin of rabbits for 4 
hours under occlusion, was not irritating 
to the skin. The structure-activity relation-
ship model (Deductive Estimation of Risk 
from Existing Knowledge, or DEREK™, 
for Windows) predicted BE to be nega-
tive for skin irritation. 
Taken together, the positive results from the 
human repeat-insult patch test [Greenspan 
et al. 1995] and from the clinical studies 
in experimental animals [Union Carbide 
Corporation 1972; Duprat and Gradiski 
1979; Zissu 1995] sufficiently demonstrate 
that BE is a mild to moderate skin irritant. 
Therefore, on the basis of the data for this 




No case reports have indicated, on the basis 
of occupational exposure, that BE is a skin 
sensitizer. However, one study evaluated the 
potential of BE to cause skin sensitization 
or photosensitization in humans. Greens-
pan et al. [1995] conducted a repeat-insult 
patch test with more than 200 volunteers, 
using a 10% aqueous solution of BE. Those 
investigators found no evidence of skin sen-
sitization elicited by BE. In guinea pigs, the 
potential for BE to be a skin sensitizer was 
investigated in the Magnusson and Klig-
man skin sensitization test [Zissu 1995]. 
However, the authors concluded that the 
substance did not elicit a positive skin re-
sponse in excess of that seen in control ani-
mals. DEREK™ predicted BE to be nega-
tive for skin sensitization. 
A limited number of studies in humans 
and animals concerning the potential of 
BE to cause skin sensitization were iden-
tified. However, the negative results in the 
human repeat-insult patch study [Greens-
pan et al. 1995] and the guinea pig maxi-
mization test [Zissu 1995] are sufficient to 
demonstrate that BE is not a skin sensi-
tizer in humans or animals. Therefore, on 
the basis of the data for this assessment, 
BE is not assigned the SK: SEN notation. 
5 Summary
Sufficient information was available from 
human and animal dermal toxicokinetic 
studies in vivo and in vitro [Bartnik et al. 
1987; Sabourin et al. 1992, 1993; Jakasa 
et al. 2004] and from dermal toxicity stud-
ies [Carpenter et al. 1956; Duprat and 
Gradiski 1979] to demonstrate that BE is 
absorbed through the skin, is systemically 
available, and can elicit systemic effects 
such as hemoglobinuria (and other blood 
effects and changes in body weight). Posi-
tive results from the single human repeat-
insult patch test [Greenspan et al. 1995] 
and from the clinical studies in experi-
mental animals [Union Carbide Corpo-
ration 1972; Duprat and Gradiski 1979; 
Zissu 1995] sufficiently demonstrate that 
BE is a mild to moderate skin irritant. Al-
though a limited number of human and 
animal studies were identified concerning 
the potential of the substance to be a skin 
sensitizer, negative results in the human 
repeat-insult patch study [Greenspan et 
al. 1995], and the guinea pig maximization 
test [Zissu 1995] are sufficient to demon-
strate that BE is not likely to be a skin 
sensitizer in humans or animals. There-
fore, on the basis of these assessments, BE 
is assigned a composite skin notation of 
SK: SYS-DIR (IRR). 
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Table 3 summarizes the skin hazard desig-
nations for BE previously issued by NIOSH 
and other organizations. The equivalent 
dermal designations for BE, according to 
the Global Harmonization System (GHS) 
of Classification and Labelling of Chemi-
cals, are Acute Toxicity Category 4 (Haz-
ard statement: Harmful in contact with the 
skin) and Skin Irritation Category 2 (Haz-
ard statement: Causes skin irritation) [Eu-
ropean Parliament 2008]. 
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the skin and respiratory absorption routes, 
and (3) evaluating whether the substance 
poses a skin exposure hazard.
The algorithm is flexible in the data re-
quirement and can operate entirely on the 
basis of the physicochemical properties 
of a substance and the relevant exposure 
parameters. Thus, the algorithm is inde-
pendent of the need for biologic data. Al-
ternatively, it can function with both the 
physicochemical properties and the ex-
perimentally determined permeation co-
efficient when such data are available and 
appropriate for use.
The first step in the evaluation is to deter-
mine the Kp for the substance to describe 
the transdermal penetration rate of the 
substance [NIOSH 2009]. The Kp, which 
represents the overall diffusion of the sub-
stance through the stratum corneum and 
into the blood capillaries of the dermis, is 
estimated from the compound’s molecular 
weight (MW) and base-10 logarithm of 
its octanol–water partition coefficient (log 
KOW). In this example, Kp is determined 
for a substance with use of Equation 1. A 
self-consistent set of units must be used, 
such as cm/hr, outlined in Table A1. Oth-
er model-based estimates of Kp may also 
be used [NIOSH 2009].
Equation 1: Calculation of Skin Permeation 
Coefficient (Kp)
*Zissu D [1995] Experimental study of cutaneous 
tolerance to glycol ethers. Contact Dermatitis 
32(2):74–77.
This appendix presents an overview of the 
SI ratio and a summary of the calculation 
of the SI ratio for BE. Although the SI 
ratio is considered in the determination of 
a substance’s hazard potential following 
skin contact, it is intended only to serve as 
supportive data during the assignment of 
the NIOSH SK. An in-depth discussion 
on the rationale and calculation of the SI 
ratio can be found in Appendix B of the 
Current Intelligence Bulletin (CIB) 61: A 
Strategy for Assigning New NIOSH Skin 
Notations [NIOSH 2009]. 
Overview 
The SI ratio is a predictive algorithm for 
estimating and evaluating the health haz-
ards of skin exposure to substances. The al-
gorithm is designed to evaluate the poten-
tial for a substance to penetrate the skin 
and induce systemic toxicity [NIOSH 
2009]. The goals for incorporating this 
algorithm into the proposed strategy for 
assigning the SYS notation are as follows:
1. Provide an alternative method to 
evaluate substances for which no 
clinical reports or animal toxicity 
studies exist or for which empirical 
data are insufficient to determine 
systemic effects.
2. Use the algorithm evaluation re-
sults to determine whether a sub-
stance poses a skin absorption haz-
ard and should be labeled with the 
SYS notation.
The algorithm evaluation includes three 
steps: (1) determining a skin permeation 
coefficient (Kp) for the substance of in-
terest, (2) estimating substance uptake by 
Appendix: Calculation of the SI Ratio for BE
where Kpsc is the permeation coefficient in 
the lipid fraction of the stratum corneum, 
Kpol is the coefficient in the protein 
fraction of the stratum corneum, and Kaq 
is the coefficient in the watery epidermal 
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Table A1. Summary of data used to calculate the SI ratio for BE 
Variables used in calculation Units Value
Skin permeation coefficient
Permeation coefficient of stratum corneum lipid path(Kpsc) cm/hr 0.00173
Permeation coefficient of the protein fraction of the 
stratum corneum (Kpol)
cm/hr 1.39717 × 10-5
Permeation coefficient of the watery epidermal layer (Kaq) cm/hr 0.22995
Molecular weight (MW)* amu 118
Base-10 logarithm of its octanol–water partition 
coefficient (log KOW)*
None 0.83
Calculated skin permeation coefficient (Kp) cm/hr 0.00173
Skin dose
Water solubility (SW)* mg/cm
3
1000
Calculated skin permeation coefficient (Kp) cm/hr 0.00173
Estimated skin surface area (palms of hand) cm
2
360
Exposure time hr 8
Calculated skin dose mg 4987.87
Inhalation dose






Retention factor (RF) None 0.75
Inhalation dose mg 180
Skin dose–to–inhalation dose (SI) ratio None 27.7
*Variables identified from SRC [2009].
†The OEL used in calculation of the SI ratio was the NIOSH-recommended exposure limit (REL) [NIOSH 2005].
layer. These components are individually 
estimated by
log Kpsc = −1.326 + 0.6097 × log KOW − 
0.1786 × MW0.5
Kpol = 0.0001519 × MW−0.5
Kaq = 2.5 × MW−0.5
The second step is to calculate the bio-
logic mass uptake of the substance from 
skin absorption (skin dose) and inhalation 
(inhalation dose) during the same period 
of exposure. The skin dose is calculated 
as a mathematical product of the Kp, the 
water solubility (SW) of the substance, the 
exposed skin surface area, and the dura-
tion of exposure. Its units are milligrams 
(mg). Assume that the skin exposure con-
tinues for 8 hours to unprotected skin on 
the palms of both hands (a surface area of 
360 cm2).
Equation 2: Determination of Skin Dose 
Skin dose = Kp × SW × Exposed skin sur-
face area × Exposure time
= Kp(cm/hr) × SW (mg/cm3) × 
360 cm2 × 8 hours
The inhalation dose (in mg) is derived 
on the basis of the occupational exposure 
limit (OEL) of the substance—if the OEL 
is developed to prevent the occurrence of 
systemic effects rather than sensory/irritant 
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effects or direct effects on the respiratory 
tract. Assume a continuous exposure of 8 
hours, an inhalation volume of 10 cubic 
meters (m3) inhaled air in 8 hours, and a 
factor of 75% for retention of the airborne 
substance in the lungs during respiration 
(retention factor, or RF).
Equation 3: Determination of Inhalation Dose
Inhalation dose = OEL × Inhalation 
 volume × RF
= OEL (mg/m3) × 10 m3 
× 0.75
The final step is to compare the calculated 
skin and inhalation doses and to present 
the result as a ratio of skin dose to inhala-
tion dose (the SI ratio). This ratio quan-
titatively indicates (1) the significance 
of dermal absorption as a route of occu-
pational exposure to the substance and 
(2)  the contribution of dermal uptake to 
systemic toxicity. If a substance has an SI 
ratio greater than or equal to 0.1, it is con-
sidered a skin absorption hazard.
Calculation 
Table A1 summarizes the data applied in 
the previously described equations to de-
termine the SI ratio for BE. The calculated 
SI ratio was 27.7. On the basis of these 
results, BE is predicted to represent a skin 
absorption hazard.
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